CL2011001296A1 - Anticuerpo monoclonal capaz de inhibir la dimerizacion de cmet; acido nucleico, vector y celula huesped que comprenden las secuencias que codifican el anticuerpo; composicion que comprende el anticuerpo; uso del anticuerpo para inhibir el crecimiento y/o proliferacion de celulas tumorales. - Google Patents

Anticuerpo monoclonal capaz de inhibir la dimerizacion de cmet; acido nucleico, vector y celula huesped que comprenden las secuencias que codifican el anticuerpo; composicion que comprende el anticuerpo; uso del anticuerpo para inhibir el crecimiento y/o proliferacion de celulas tumorales.

Info

Publication number
CL2011001296A1
CL2011001296A1 CL2011001296A CL2011001296A CL2011001296A1 CL 2011001296 A1 CL2011001296 A1 CL 2011001296A1 CL 2011001296 A CL2011001296 A CL 2011001296A CL 2011001296 A CL2011001296 A CL 2011001296A CL 2011001296 A1 CL2011001296 A1 CL 2011001296A1
Authority
CL
Chile
Prior art keywords
antibody
proliferation
inhibit
vector
growth
Prior art date
Application number
CL2011001296A
Other languages
English (en)
Spanish (es)
Inventor
Liliane Goetsch
Thierry Wurch
Cedric Bes
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41693124&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2011001296(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/IB2008/055663 external-priority patent/WO2010064089A1/en
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of CL2011001296A1 publication Critical patent/CL2011001296A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Connection Of Motors, Electrical Generators, Mechanical Devices, And The Like (AREA)
  • Medicinal Preparation (AREA)
CL2011001296A 2008-12-02 2011-06-01 Anticuerpo monoclonal capaz de inhibir la dimerizacion de cmet; acido nucleico, vector y celula huesped que comprenden las secuencias que codifican el anticuerpo; composicion que comprende el anticuerpo; uso del anticuerpo para inhibir el crecimiento y/o proliferacion de celulas tumorales. CL2011001296A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2008/055663 WO2010064089A1 (en) 2008-12-02 2008-12-02 Novel anti-cmet antibody
US18450209P 2009-06-05 2009-06-05

Publications (1)

Publication Number Publication Date
CL2011001296A1 true CL2011001296A1 (es) 2011-08-26

Family

ID=41693124

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2011001296A CL2011001296A1 (es) 2008-12-02 2011-06-01 Anticuerpo monoclonal capaz de inhibir la dimerizacion de cmet; acido nucleico, vector y celula huesped que comprenden las secuencias que codifican el anticuerpo; composicion que comprende el anticuerpo; uso del anticuerpo para inhibir el crecimiento y/o proliferacion de celulas tumorales.
CL2014000181A CL2014000181A1 (es) 2008-12-02 2014-01-24 Anticuerpo monoclonal capaz de inhibir la dimerización de receptor para el factor del crecimiento de hepatocitos (c-met); acido nucleico aislado que lo codifica; vector y célula huesped que lo comprenden; proceso para la produccion del anticuerpo; uso del anticuerpo para tratar cancer (divisional de la solicitud 1296-11).

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2014000181A CL2014000181A1 (es) 2008-12-02 2014-01-24 Anticuerpo monoclonal capaz de inhibir la dimerización de receptor para el factor del crecimiento de hepatocitos (c-met); acido nucleico aislado que lo codifica; vector y célula huesped que lo comprenden; proceso para la produccion del anticuerpo; uso del anticuerpo para tratar cancer (divisional de la solicitud 1296-11).

Country Status (38)

Country Link
US (4) US8741290B2 (enExample)
EP (4) EP3135691B1 (enExample)
JP (3) JP5863458B2 (enExample)
KR (1) KR101838299B1 (enExample)
CN (2) CN102227446B (enExample)
AR (1) AR074439A1 (enExample)
AU (3) AU2009328318C1 (enExample)
BR (2) BR122019023930B1 (enExample)
CA (1) CA2743433C (enExample)
CL (2) CL2011001296A1 (enExample)
CO (1) CO6382139A2 (enExample)
CR (1) CR20110324A (enExample)
CY (2) CY1119172T1 (enExample)
DK (2) DK3135691T3 (enExample)
EC (1) ECSP11011127A (enExample)
ES (3) ES2629855T3 (enExample)
GE (2) GEP20146207B (enExample)
HR (2) HRP20171011T8 (enExample)
HU (3) HUE035047T2 (enExample)
IL (2) IL213273A0 (enExample)
LT (2) LT2370468T (enExample)
MA (1) MA32892B1 (enExample)
MX (2) MX2011005677A (enExample)
MY (2) MY192567A (enExample)
NZ (1) NZ593853A (enExample)
PE (1) PE20120343A1 (enExample)
PH (1) PH12015501515A1 (enExample)
PL (3) PL3135691T3 (enExample)
PT (3) PT3135691T (enExample)
RS (2) RS58018B1 (enExample)
RU (2) RU2015127471A (enExample)
SA (2) SA112331005B1 (enExample)
SG (2) SG171851A1 (enExample)
SI (3) SI2370468T1 (enExample)
TN (1) TN2011000216A1 (enExample)
TW (2) TWI459964B (enExample)
WO (1) WO2010069765A1 (enExample)
ZA (1) ZA201105164B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014681A1 (en) 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
EP2287197A1 (en) * 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
RU2013114783A (ru) 2010-09-03 2014-10-10 Академиа Синика Anti-с-мет антитела и способы их применения
BR122014027420A2 (pt) 2010-11-03 2019-08-20 Argenx Bvba Anticorpos anti c-met
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
KR101865223B1 (ko) 2011-10-05 2018-06-08 삼성전자주식회사 항 ｃ-Ｍｅｔ 인간화 항체 및 그의 용도
KR20130036993A (ko) * 2011-10-05 2013-04-15 삼성전자주식회사 ｃ-Ｍｅｔ의 ＳＥＭＡ 도메인 내의 에피토프에 특이적으로 결합하는 항체
EP2773660A2 (en) 2011-11-03 2014-09-10 Argen-X B.V. Chimeric human-camel antigens and their use
KR101463098B1 (ko) * 2011-11-28 2014-11-27 한국생명공학연구원 ｃ-Ｍｅｔ에 대한 인간항체에 약물이 접합된 약물 복합체 및 이의 용도
US8900582B2 (en) 2011-12-22 2014-12-02 Samsung Electronics Co., Ltd. Deimmunized anti c-Met humanized antibodies and uses thereof
EP2863946A4 (en) 2012-06-21 2016-04-13 Sorrento Therapeutics Inc ANTIGEN-BINDING PROTEINS THAT BIND TO C-MET
EP2708556B1 (en) 2012-09-12 2018-11-07 Samsung Electronics Co., Ltd Pharmaceutical composition for the use in a combination therapy for prevention or treatment of c-met or angiogenesis factor induced diseases
WO2014057074A1 (en) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazepines and conjugates thereof
AU2014230735B2 (en) 2013-03-13 2018-03-15 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
KR102049990B1 (ko) * 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9994644B2 (en) 2013-04-30 2018-06-12 Agency For Science, Technology And Research mAB 2 anti-Met antibody
US9567641B2 (en) * 2013-07-03 2017-02-14 Samsung Electronics Co., Ltd. Combination therapy for the treatment of cancer using an anti-C-met antibody
US9717715B2 (en) 2013-11-15 2017-08-01 Samsung Electronics Co., Ltd. Method of combination therapy using an anti-C-Met antibody
ES2729797T3 (es) * 2013-12-20 2019-11-06 Dev Ct Biotechnology Anticuerpos específicos de la alfa-enolasa y métodos de uso en terapias contra el cáncer
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US20180057595A1 (en) * 2015-03-16 2018-03-01 Celldex Therapeutics, Inc. Anti-MET Antibodies and Methods of Use Thereof
EP3411067B1 (en) * 2016-02-05 2021-10-20 Helixmith Co., Ltd Anti-c-met antibodies and uses thereof
US10870701B2 (en) 2016-03-15 2020-12-22 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
MX2018014175A (es) * 2016-05-17 2020-02-07 Abbvie Biotherapeutics Inc Conjugados de anticuerpo-fármaco anti-cmet y métodos para su uso.
US10457726B2 (en) 2016-06-30 2019-10-29 University Of Connecticut Antibody and antigen-binding fragment compositions targeting cell surface antigens in tumors and methods of use thereof
US20200023072A1 (en) 2016-10-11 2020-01-23 Medimmune Limited Antibody-drug conjugates with immune-mediated therapy agents
WO2018088933A1 (en) * 2016-11-14 2018-05-17 Limited Liability Company "Panacela Labs" Anti-tumor effects of a viral vector encoding a toll-like receptor and a toll-like receptor agonist
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
US20180230218A1 (en) * 2017-01-04 2018-08-16 Immunogen, Inc. Met antibodies and immunoconjugates and uses thereof
CN109771642B (zh) * 2017-11-13 2022-09-20 同济大学苏州研究院 c-MET激动型抗体及其用途
GB201803892D0 (en) * 2018-03-12 2018-04-25 Ultrahuman Six Ltd C-met binding agents
BR112020023846A2 (pt) 2018-05-23 2021-04-13 Adc Therapeutics Sa Adjuvante molecular
MA53284A (fr) * 2018-08-08 2022-01-26 Dragonfly Therapeutics Inc Protéines de liaison à nkg2d, à cd16 et à un antigène associé à une tumeur
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
CN109541221B (zh) * 2018-10-24 2022-03-22 益善生物技术股份有限公司 一种c-Met特异性抗体、组合物及试剂盒
KR102353568B1 (ko) 2018-11-14 2022-01-20 주식회사 헬릭스미스 안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
JP7662531B2 (ja) * 2019-03-28 2025-04-15 ダニスコ・ユーエス・インク 改変抗体
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白
WO2022079211A1 (en) 2020-10-16 2022-04-21 Adc Therapeutics Sa Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
AU2022253888A1 (en) 2021-04-06 2023-09-28 AbbVie Manufacturing Management Unlimited Company Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin
WO2022214517A1 (en) * 2021-04-08 2022-10-13 Byondis B.V. Anti-c-met antibodies and antibody-drug conjugates
UY39743A (es) * 2021-04-29 2022-11-30 Abbvie Inc Conjugados de anticuerpo anti-c-met y fármaco
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody
WO2023173109A1 (en) 2022-03-11 2023-09-14 Abbvie Biotherapeutics Inc. Methods of treatment of non-small-cell lung carcinoma using telisotuzumab vedotin and osimertinib
AU2024276234A1 (en) 2023-05-23 2025-12-04 AbbVie Manufacturing Management Unlimited Company Methods of treatment using anti-c-met antibody drug conjugates
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4424200A (en) 1979-05-14 1984-01-03 Nuc Med Inc. Method for radiolabeling proteins with technetium-99m
US4479930A (en) 1982-07-26 1984-10-30 Trustees Of The University Of Massachusetts Amines coupled wth dicyclic dianhydrides capable of being radiolabeled product
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4831175A (en) 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8924581D0 (en) 1989-11-01 1989-12-20 Pa Consulting Services Bleaching of hair
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
EP1349574A2 (en) * 2001-01-09 2003-10-08 MERCK PATENT GmbH Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
CA2516236A1 (en) * 2003-02-13 2004-08-26 Pharmacia Corporation Antibodies to c-met for the treatment of cancers
HN2004000285A (es) 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
CN1922208A (zh) * 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
ME01803B (me) 2004-08-05 2010-12-31 Genentech Inc Humanizovani anti-cmet antagonisti
JP5255435B2 (ja) * 2005-04-26 2013-08-07 メディミューン，エルエルシー ヒンジドメイン操作による抗体エフェクター機能の調節
RS54984B1 (sr) 2005-07-18 2016-11-30 Amgen Inc Humana anti-b7rp1 neutrališuća antitela
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
CN103183738B (zh) * 2006-03-30 2014-08-06 诺瓦提斯公司 c-Met抗体的组合物和使用方法
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
US8545839B2 (en) 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody

Also Published As

Publication number Publication date
EP2370468A1 (en) 2011-10-05
JP2017099392A (ja) 2017-06-08
CN103351438A (zh) 2013-10-16
TWI523866B (zh) 2016-03-01
SA109300720B1 (ar) 2013-05-25
CN102227446A (zh) 2011-10-26
US8765128B2 (en) 2014-07-01
EP3431502A1 (en) 2019-01-23
RU2015127471A (ru) 2018-12-21
SG171851A1 (en) 2011-07-28
CA2743433C (en) 2019-06-11
EP3135691A1 (en) 2017-03-01
SA112331005B1 (ar) 2015-09-13
CY1121025T1 (el) 2019-12-11
US8747850B2 (en) 2014-06-10
HUE035047T2 (en) 2018-05-02
CL2014000181A1 (es) 2014-07-25
AR074439A1 (es) 2011-01-19
PT3135691T (pt) 2018-11-27
HRP20171011T8 (hr) 2019-01-25
IL213273A0 (en) 2011-07-31
CN103351438B (zh) 2016-04-20
SI3135691T1 (sl) 2018-12-31
MX341014B (es) 2016-08-03
MY192567A (en) 2022-08-29
MX2011005677A (es) 2011-06-30
RS56204B1 (sr) 2017-11-30
DK2370468T3 (en) 2017-06-19
SI3431502T1 (sl) 2021-01-29
JP5863458B2 (ja) 2016-02-16
RS58018B1 (sr) 2019-02-28
JP6309657B2 (ja) 2018-04-11
US8729249B2 (en) 2014-05-20
AU2016200725A1 (en) 2016-02-25
KR20110097839A (ko) 2011-08-31
AU2009328318B2 (en) 2015-11-05
HK1162536A1 (zh) 2012-08-31
PL2370468T3 (pl) 2017-09-29
SI2370468T1 (sl) 2017-08-31
GEP20146207B (en) 2014-12-10
NZ593853A (en) 2013-03-28
US20110239316A1 (en) 2011-09-29
KR101838299B1 (ko) 2018-03-14
BR122019023930B1 (pt) 2021-05-04
LT2370468T (lt) 2017-07-10
AU2016200725C1 (en) 2017-10-19
CO6382139A2 (es) 2012-02-15
CY1119172T1 (el) 2018-02-14
PT2370468T (pt) 2017-07-13
TN2011000216A1 (en) 2012-12-17
HUE040553T2 (hu) 2019-03-28
ES2629855T3 (es) 2017-08-16
EP2370468B1 (en) 2017-04-05
PE20120343A1 (es) 2012-04-16
US8741290B2 (en) 2014-06-03
AU2016200725B2 (en) 2017-05-25
HRP20181868T1 (hr) 2019-01-11
BRPI0923231A2 (pt) 2016-01-26
PL3135691T3 (pl) 2019-02-28
JP2012510280A (ja) 2012-05-10
ZA201105164B (en) 2012-03-28
US20130109840A1 (en) 2013-05-02
CR20110324A (es) 2011-07-28
HK1190414A1 (zh) 2014-07-04
IL231525A0 (en) 2014-04-30
LT3135691T (lt) 2018-11-12
AU2009328318C1 (en) 2017-11-02
ES2697098T3 (es) 2019-01-22
US20130109844A1 (en) 2013-05-02
JP2016117721A (ja) 2016-06-30
CN102227446B (zh) 2015-10-21
AU2009328318A1 (en) 2011-07-28
PH12015501515A1 (en) 2015-12-14
MY185200A (en) 2021-04-30
RU2011124751A (ru) 2013-01-10
BRPI0923231B8 (pt) 2021-05-25
HUE051288T2 (hu) 2021-03-01
TW201446805A (zh) 2014-12-16
AU2017203929B2 (en) 2019-03-28
AU2017203929A1 (en) 2017-07-06
ECSP11011127A (es) 2011-07-29
HRP20171011T1 (hr) 2017-09-22
US20130109841A1 (en) 2013-05-02
JP6074018B2 (ja) 2017-02-01
DK3135691T3 (en) 2018-11-19
RU2560257C2 (ru) 2015-08-20
MA32892B1 (fr) 2011-12-01
BRPI0923231B1 (pt) 2020-04-28
ES2827277T3 (es) 2021-05-20
WO2010069765A1 (en) 2010-06-24
EP3135691B1 (en) 2018-08-15
TWI459964B (zh) 2014-11-11
CA2743433A1 (en) 2010-06-24
TW201023892A (en) 2010-07-01
EP3431502B1 (en) 2020-07-22
IL231525B (en) 2019-07-31
PL3431502T3 (pl) 2020-12-28
GEP20135930B (en) 2013-10-10
PT3431502T (pt) 2020-10-29
EP3757132A1 (en) 2020-12-30
SG187518A1 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
CL2011001296A1 (es) Anticuerpo monoclonal capaz de inhibir la dimerizacion de cmet; acido nucleico, vector y celula huesped que comprenden las secuencias que codifican el anticuerpo; composicion que comprende el anticuerpo; uso del anticuerpo para inhibir el crecimiento y/o proliferacion de celulas tumorales.
AR113177A2 (es) Polipéptidos que tienen actividad de lisozima y polinucleótidos que los codifican
MX2013012844A (es) Secuencias de aminoacidos dirigidas contra il-17a, il-17f y/o il-17a/f y polipeptidos que comprenden las mismas.
JO3519B1 (ar) تركيبات أجسام مضادة لأجل cdh19 و cd3
CL2009000082A1 (es) Acido nucleico que codifica anticuerpos anti cd79a o anti cd79b para el tratamiento de tumores hematopoyeticos; vector y células huésped que los comprenden; polipeptido codificado por dicho acido nucleico, inmunoconjugado con el cuerpo.
CO6670523A2 (es) Anticuerpos específicos para proteína de activación fibroblástica (fap), polinucleotidos que codifican dichos anticuerpos, y vectores y células huesped que comprenden dichos nucleótidos
ES2691070T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
BR112016027585A2 (pt) construções de anticorpo multiespecíficas
MX337984B (es) Variantes de alfa amilasa y polinucleotidos que codifican la misma.
CL2017002514A1 (es) Anticuerpos anti-c1s humanizados y métodos para usarlos.
BR112013019028A2 (pt) derivados de 7-azaindol
GEP20196976B (en) Newcastle disease viruses and uses thereof
GB201020995D0 (en) Biological materials and uses thereof
ES2693321T3 (es) Péptidos antiinflamatorios y composición que comprende los mismos
ECSP12011691A (es) Compuestos de urea que contienen heteroarilo 5,6-bicíclicos como inhibidores de quinasa
CL2011002039A1 (es) Anticuerpo humanizado que se une al cd19 humano; acido nucleico aislado que codifica dicho anticuerpo; vector y celula huesped; composicion e inmunoconjugado; metodo para inhibir el crecimiento de celulas de tumor que expresan cd19.
MX372679B (es) Moleculas de union para bcma y cd3.
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
EA201201016A1 (ru) Антидоты антикоагулянтов
CL2016000344A1 (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
AR093446A1 (es) Anticuerpos de antihemaglutinina y metodos de uso
CL2007002926A1 (es) Anticuerpo antilinfotoxina alfa (lt-alfa); composicion con el anticuerpo; hibridoma pta-7538; acido nucleico codificante del anticuerpo; vector y celula huesped que comprenden el acido nucleico; metodo para inhibir la proliferacion celular activada p
BR112015020290A2 (pt) métodos para tratar um câncer, para prevenir câncer, para inibir proliferação, para tratar terapeuticamente um mamífero, para tratar uma disfunção, para reduzir níveis de proteína spp1, para tratar terapeuticamente um câncer, para tratar um indivíduo e para inibir proliferação celular, artigo, anticorpos e usos
EA201301130A1 (ru) Имидазопиридазины в качестве ингибиторов акт киназы
MX349048B (es) Nuevos marcadores de la diferenciacion de th17 para el acne y usos de los mismos.